Gastrointestinal Conditions: Peptic Ulcer Disease.

Q3 Medicine FP essentials Pub Date : 2024-05-01
Justin M Bailey
{"title":"Gastrointestinal Conditions: Peptic Ulcer Disease.","authors":"Justin M Bailey","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Peptic ulcer disease (PUD) involves ulceration of the mucosa in the stomach and/or proximal duodenum. The main causes are Helicobacter pylori infection and nonsteroidal anti-inflammatory drug (NSAID) use. PUD occurs in 5% to 10% of people worldwide, but rates have decreased by more than half during the past 20 years. This reduction is thought to be because of H pylori management, more conservative use of NSAIDs, and/or widespread use of proton pump inhibitors (PPIs). Common symptoms include postprandial abdominal pain, nausea, vomiting, and weight loss. These symptoms have broad overlap with those of other conditions, making clinical diagnosis difficult. Endoscopy is the gold standard for diagnosis, especially in older patients and those with alarm symptoms, but a test-and-treat strategy (noninvasive test for H pylori and treat if positive) can be used for younger patients with no alarm symptoms. Numerous treatment regimens are available, all of which include PPIs plus antibiotics. As an alternative to PPIs, a new triple therapy with vonoprazan (which blocks acid production) plus antibiotics has been approved and appears to be superior to conventional therapy with PPIs plus antibiotics. At least 4 weeks after treatment, repeat testing for H pylori should be obtained to confirm cure. When possible, NSAIDs should be discontinued; when not possible, antisecretory cotherapy should be considered.</p>","PeriodicalId":38325,"journal":{"name":"FP essentials","volume":"540 ","pages":"16-23"},"PeriodicalIF":0.0000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"FP essentials","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Peptic ulcer disease (PUD) involves ulceration of the mucosa in the stomach and/or proximal duodenum. The main causes are Helicobacter pylori infection and nonsteroidal anti-inflammatory drug (NSAID) use. PUD occurs in 5% to 10% of people worldwide, but rates have decreased by more than half during the past 20 years. This reduction is thought to be because of H pylori management, more conservative use of NSAIDs, and/or widespread use of proton pump inhibitors (PPIs). Common symptoms include postprandial abdominal pain, nausea, vomiting, and weight loss. These symptoms have broad overlap with those of other conditions, making clinical diagnosis difficult. Endoscopy is the gold standard for diagnosis, especially in older patients and those with alarm symptoms, but a test-and-treat strategy (noninvasive test for H pylori and treat if positive) can be used for younger patients with no alarm symptoms. Numerous treatment regimens are available, all of which include PPIs plus antibiotics. As an alternative to PPIs, a new triple therapy with vonoprazan (which blocks acid production) plus antibiotics has been approved and appears to be superior to conventional therapy with PPIs plus antibiotics. At least 4 weeks after treatment, repeat testing for H pylori should be obtained to confirm cure. When possible, NSAIDs should be discontinued; when not possible, antisecretory cotherapy should be considered.

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
胃肠道疾病:消化性溃疡病
消化性溃疡病(PUD)是指胃黏膜和/或十二指肠近端发生溃疡。主要原因是幽门螺旋杆菌感染和使用非甾体抗炎药(NSAID)。全世界有 5%-10%的人患有 PUD,但在过去 20 年中,发病率下降了一半以上。据认为,发病率下降的原因是幽门螺杆菌得到了控制、非甾体抗炎药的使用更加保守和/或质子泵抑制剂(PPI)的广泛使用。常见症状包括餐后腹痛、恶心、呕吐和体重减轻。这些症状与其他疾病的症状有广泛的重叠,给临床诊断带来困难。内镜检查是诊断的金标准,尤其是对于老年患者和有报警症状的患者,但对于没有报警症状的年轻患者,可以采用先检测后治疗的策略(无创幽门螺杆菌检测,如果呈阳性则进行治疗)。目前有许多治疗方案,其中都包括 PPIs 和抗生素。作为 PPIs 的替代疗法,vonoprazan(可阻断胃酸分泌)加抗生素的新型三联疗法已获得批准,该疗法似乎优于 PPIs 加抗生素的传统疗法。治疗至少 4 周后,应再次检测幽门螺杆菌以确认治愈。在可能的情况下,应停用非甾体抗炎药;在不可能的情况下,应考虑抗分泌物疗法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
FP essentials
FP essentials Medicine-Medicine (all)
CiteScore
1.00
自引率
0.00%
发文量
58
期刊最新文献
Female Pelvic Conditions: Dyspareunia and Vulvodynia. Female Pelvic Conditions: Foreword. Female Pelvic Conditions: Interstitial Cystitis/Bladder Pain Syndrome. Female Pelvic Conditions: Sexually Transmitted Infections. Female Pelvic Conditions: Urinary Incontinence.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1